ASX: IPD

28 April 2015

**ASX ANNOUNCEMENT**

## L-Dex® trial adds another NCI designated cancer center

### HIGHLIGHTS

- University of Kansas Cancer Center (KUCC), an NCI designated cancer center, has joined the L-Dex post-approval trial[1]
- Principal Investigator is KUCC assistant professor of surgery, breast surgery division, Jamie Wagner, DO, FACOS

Brisbane, Australia – ImpediMed Limited (ASX: IPD) ("the Company") is pleased to announce that University of Kansas Cancer Center in Kansas City, Kansas has joined the list of National Cancer Institute (NCI) designated comprehensive cancer centers for the L-Dex international, post-approval clinical trial.

Dr Jamie Wagner has been named principal investigator for this trial site. She is a member of a number of associations including the National Lymphedema Network's Medical Advisory Committee. "I am passionate and dedicated about helping my patients through the diagnosis, treatment and survival of breast cancer. This trial should answer the critical question in lymphedema assessment of the best detection technique to improve patient outcomes," said Dr Wagner.

"We are very pleased to have Dr Wagner and KUCC added to the list of illustrious researchers involved in the post-approval clinical trial of L-Dex," said Richard Carreon, CEO of ImpediMed.

Details of the clinical trial can be found at the US National Institutes of Health website: http://clinicaltrials.gov/ct2/show/NCT02167659?term=impedimed&rank=6

[1] Previous announcements at ASX on 30th October 2013, 26th June 2014, 23rd July 2014, 5th March 2015 and 9th March 2015

**Richard Carreon**
**CEO**

**ENDS**

**For further information contact:**
**Richard Carreon, ImpediMed CEO**
**Morten Vigeland, ImpediMed CFO**
**T: +1 (760) 585-2100**

**Kyahn Williamson, Buchan**
**Investor and Media Relations**
**T: +61 3 9866 4722**
**E: kwilliamson@buchanwe.com.au**

**About ImpediMed**
ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au